证券代码：300573 证券简称：兴齐眼药 公告编号：2023-041 沈阳兴齐眼药股份有限公司 关于控股股东、实际控制人部分股份质押延期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称："公司"）近日接到控股股东、实际 控制人刘继东先生的通知，获悉其所持有本公司的部分股份办理了质押延期购回 业务，具体事项如下： | 股东 | 是否为 控股股 东或第 一大股 | 本次延期 股份数量 | 占其所 持股份 | 占公 司总 | 是否 为限 | 是否 为补 | 原质押 | 原质押 | 延期后 质押到 | 质权 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其 | （股） | 比例 | 股本 | 售股 | 充质 | 开始日 | 到期日 | 期日 | 人 | 用途 | | | 一致行 | | | 比例 | | 押 | | | | | | | | 动人 | | | | | | | | | | | | ...

证券代码：300573 证券简称：兴齐眼药 | --- | --- | --- | --- | |------------|-------|----------------|------------------| | | □ | 特定对象调研 □ | 分析师会议 | | 投资者关系 | □ | 媒体采访 □ | 业绩说明会 | | 活动类别 | □ | 新闻发布会 | □ 路演活动 | | | □ | 现场参观 √ | 其他（电话会议） | 参与单位名称 及人员姓名 详见附件：参加交流活动人员名单 时间 2023 年 5 月 5 日 15:30-16:30（北京时间） 地点 电话会议 董事长 刘继东 副董事长、董事会秘书 张少尧 上市公司接待人 董事、总经理 高 峨 员姓名 董事、副总经理 杨 强 董事、财务总监 程亚男 全国销售总监 张辰杨 公司联合广发证券、安信证券于 2023 年 5 月 5 日召开了兴齐眼药 2022 年度及 2023 年一季度业绩交流会，公司管理层就 2022 年度及 2023 年一季度生产经营管理情况及投资者关注的问题与投资者进行了沟通和 交流内容及具体 交流。 问答记录 一、20 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 286,560,377.99, a decrease of 5.10% compared to CNY 301,958,988.82 in the same period last year[4] - Net profit attributable to shareholders was CNY 19,349,332.43, down 73.91% from CNY 74,168,573.48 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 15,561,733.77, a decrease of 79.32% compared to CNY 75,262,091.90 in the previous year[4] - Basic and diluted earnings per share were both CNY 0.22, a decrease of 73.81% from CNY 0.84 in the previous year[4] - Net profit for the period was CNY 22,867,144.85, down 74.0% from CNY 87,958,734.62 in Q1 2022[19] - The net profit for Q1 2023 was CNY 19,349,332.43, a significant improvement compared to a net loss of CNY 74,168,573.48 in the same period last year, representing a turnaround of approximately 126%[20] - The company reported a decrease in sales revenue from CNY 313,334,689.40 in Q1 2022 to CNY 283,170,181.44 in Q1 2023, a decline of about 9.6%[21] Cash Flow and Assets - The net cash flow from operating activities was CNY 58,337,902.67, down 43.53% from CNY 103,314,893.79 in the same period last year[4] - Cash and cash equivalents at the end of the quarter were CNY 485,537,595.56, a decrease from CNY 515,449,608.39 at the beginning of the year[18] - Total cash and cash equivalents at the end of Q1 2023 were CNY 484,149,429.77, down from CNY 628,417,660.68 at the end of Q1 2022, a decrease of about 22.9%[23] - Operating cash inflow for Q1 2023 was CNY 287,111,040.43, down from CNY 316,066,571.72 in Q1 2022, reflecting a decrease of about 9.2%[21] - The company invested CNY 97,838,674.51 in fixed assets and intangible assets during Q1 2023, compared to CNY 52,486,090.96 in Q1 2022, representing an increase of approximately 86.2%[22] Expenses and Liabilities - Total operating costs increased to CNY 262,441,239.37, up 22.5% from CNY 214,113,341.19 in Q1 2022[19] - Sales expenses rose by 40.64% to CNY 133,965,927.69, primarily due to increased employee compensation and meeting costs[9] - Total liabilities rose to CNY 250,015,468.98, up from CNY 230,634,015.20 at the beginning of the year[18] - The company reported a significant increase in contract liabilities to CNY 10,207,350.65, compared to CNY 2,005,290.19 in the previous period[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,961, with the largest shareholder, Liu Jidong, holding 28.59% of shares[11] - Liu Jidong holds 25,315,500 shares, with 18,986,625 shares under lock-up conditions and 3,530,000 shares pledged[11] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder holding 4.35%[11] - The company’s major shareholders do not hold shares through margin trading accounts[12] Research and Development - The company increased its R&D expenditure compared to the previous year, contributing to the decline in net profit[7] - Research and development expenses rose to CNY 28,684,039.18, an increase of 28.5% compared to CNY 22,312,058.34 in the previous year[19] - The company is actively expanding its product offerings and enhancing its technological capabilities through various certifications and approvals[16] Government Support and Certifications - The company reported a significant increase in government subsidies, with other income rising by 423.87% to CNY 5,064,032.46[9] - The company’s technology center has been recognized as a national enterprise technology center, eligible for tax benefits and policy support[14] - The subsidiary, Shenyang Xingqi Eye Hospital, has been certified as a high-tech enterprise, enjoying a reduced corporate income tax rate of 15% for three years[15] - The company’s product, Compound Electrolyte Eye Wash, has been included in the National Medical Insurance Directory[16] - The company has received a drug registration certificate for Sodium Hyaluronate Eye Drops, with approval number H20233348[16] - The company signed a project investment agreement with the Shenyang Free Trade Zone Management Committee, indicating ongoing investment activities[13] Audit Status - The company has not undergone an audit for the Q1 2023 report[24]

Financial Performance - The company reported a total revenue of CNY 1.2 billion for the fiscal year 2022, representing a year-on-year growth of 15%[29]. - The net profit attributable to shareholders was CNY 300 million, an increase of 20% compared to the previous year[29]. - The company's operating revenue for 2022 was CNY 1,249,855,370.83, representing a 21.59% increase compared to CNY 1,027,914,866.71 in 2021[34]. - The net profit attributable to shareholders for 2022 was CNY 211,684,305.31, an increase of 8.72% from CNY 194,702,374.35 in 2021[34]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[29]. - The company anticipates a revenue guidance of CNY 1.5 billion for 2023, representing a growth target of 25%[29]. - The total profit for the year was ¥233,718,204.58, which decreased by 4.03% year-on-year[56]. - The company achieved quarterly revenues of CNY 301,958,988.82 in Q1, CNY 298,613,531.46 in Q2, CNY 403,699,656.59 in Q3, and CNY 245,583,193.96 in Q4 of 2022[36]. Research and Development - The company is committed to improving its R&D capabilities and expanding its product pipeline to address risks related to unmet expectations in R&D projects[10]. - Research and development expenses accounted for 12% of total revenue, reflecting the company's commitment to innovation[29]. - The company intends to broaden its ophthalmic product line and increase R&D investments to stay competitive in a rapidly evolving market[8]. - The company’s R&D efforts led to the approval of new drug specifications for Moxifloxacin eye drops and the initiation of clinical trials for Voriconazole eye drops[62]. - The company is developing new drugs for retinal diseases, including SQ-21127 and SQ-129, which are in the preclinical research stage[85]. - The total R&D investment for 2022 was ¥190,199,971.05, accounting for 15.22% of operating revenue, up from 11.47% in 2021[86]. - The number of R&D personnel increased by 11.05% to 191, with a significant rise in master's degree holders by 66.15%[86]. Market Expansion and Strategy - The company aims to expand its market presence in Southeast Asia, projecting a revenue contribution of CNY 200 million from this region by 2024[29]. - The company is aware of the intensified internal competition within the pharmaceutical industry and will seek to explore new markets to sustain growth[9]. - The company plans to launch three new ophthalmic products in 2023, targeting a market share increase of 10% in the next fiscal year[29]. - The company is exploring market expansion opportunities in Southeast Asia, aiming for a 30% increase in international sales by 2024[196]. - A strategic acquisition of a local competitor is expected to enhance the company's product portfolio and increase market penetration by 15%[29]. Operational Efficiency and Cost Management - The company will actively seek new suppliers and manage procurement costs to counteract the rising costs of raw materials and ensure production efficiency[11]. - The company has implemented new technologies in production, which are expected to reduce costs by 5% in the next fiscal year[196]. - The company has established long-term stable relationships with suppliers for raw material procurement, ensuring quality and reliability[52]. - The production center will optimize production strategies to ensure sustained supply after products enter the medical insurance directory[111]. Corporate Governance and Management - The board of directors consists of 9 members, including 3 independent directors, complying with relevant laws and regulations[122]. - The supervisory board has 3 members, including 1 employee representative, meeting legal requirements[123]. - The company has established a strict internal control management system covering decision-making, asset management, procurement, and financial reporting[124]. - The company maintains independence from its controlling shareholders in business operations, personnel, assets, and financial matters[129][130][131][132][133]. - The company has a structured remuneration scheme approved by the shareholders' meeting[146]. - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 14.24 million[149]. Environmental Compliance and Social Responsibility - The company has implemented a wastewater treatment process using pre-treatment, A/O, and MBR methods, ensuring that all treated wastewater meets national and local regulatory standards[197]. - The company has invested a total of 2.1 million yuan in environmental protection in 2022, including 1.5 million yuan in environmental facilities and 400,000 yuan for hazardous waste disposal[199]. - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental bureau[197]. - The company collaborated with local welfare foundations to support 81 low-income disabled families in developing breeding projects, contributing to local economic improvement[200]. - The company has signed donation agreements to establish "Bright Future" funds aimed at enhancing rural education and infrastructure[200]. Shareholder Engagement and Profit Distribution - The company plans to distribute a cash dividend of 10 CNY per 10 shares to all shareholders, based on a total of 88,555,082 shares[16]. - The company reported a distributable profit of 494,976,789.61 RMB for the period[166]. - The cash dividend distribution plan is subject to approval at the company's 2022 annual general meeting and aligns with the company's articles of association regarding profit distribution[169]. - The independent directors confirmed that the profit distribution plan does not harm the interests of shareholders, especially minority shareholders[169]. - The company has a clear profit distribution policy that ensures the protection of shareholders' rights, particularly for minority shareholders[164].

为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 27 日（星期四）17：00 前访问 https://ir.p5w.net/zj/进入问题征集专题 页面进行提问。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进 行回答。 证券代码：300573 证券简称：兴齐眼药 公告编号：2023-016 沈阳兴齐眼药股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）《2022 年年度报告》及摘要 已于 2023 年 4 月 20 日在巨潮资讯网（http://www.cninfo.com.cn/）予以披露， 为让广大投资者能进一步了解公司 2022 年年度报告和 2022 年生产经营情况，公 司将于 2023 年 4 月 28 日（星期五）15:00-17:00 时举行 2022 年度业绩说明会。 本次业绩说明会将采用网络远程方式举行，投资者可登陆 ...

Group 1: Market Focus and Product Development - The global focus on retinal drugs and dry eye disease is increasing, with dry eye treatment evolving beyond just hydration to include inflammation control [2] - The market for dry eye disease is expected to grow significantly, with the approval of cyclosporine showing positive clinical results [2] - Companies are developing monoclonal antibodies and small molecule drugs for retinal diseases, indicating a diverse future market [3] Group 2: Product Launch and Strategy - The product "Zirun" received national approval in June 2020, with a dedicated team responsible for 500 hospitals for clinical data collection [3] - The 0.05% cyclosporine has entered the preliminary medical insurance directory [3] Group 3: Research and Collaboration - The company is collaborating with foreign research institutions to develop small molecule anti-VEGF drugs [3] - There is a focus on developing innovative products in the field of ophthalmic devices, with plans to advance from third-generation to fourth-generation OK lenses [3] Group 4: Clinical Trials and Regulatory Compliance - The company aims to complete the enrollment for low-concentration atropine clinical trials by the end of 2020, with results expected in 2023-2024 [4] - The clinical trials for new indications must comply with national regulations, similar to new drug applications [4] Group 5: Market Competition and Challenges - There is currently no administrative protection period for low-concentration atropine, but data protection exists [4] - Other companies' formulations for preventing myopia in adolescents cannot be authorized if they are for the same indication [4]